A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing
and limited peripheral neuro-toxicity, two major potential advantages in patients with
advanced NSGCTs.
Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have
demonstrated activity in pre-treated GCTs and are now part of standard treatment, but
cabazitaxel has not yet been tested in patients with NSGCT.